Aims: To report on results of an innovative glaucoma shared-care scheme based in Peterborough, UK.
Methods: A retrospective review of all new appointments with 11 community-based specialist optometrists in glaucoma (SOG) was conducted. There are two tiers of SOG, whereby tier 2 SOGs have increased levels of autonomy. All optometrist assessments were reviewed by a consultant ophthalmologist, and levels of agreement were calculated for assessment of optic nerve head appearance, Humphrey visual field test interpretation, diagnosis and outcome.
Results: 1639 new patients were assessed by SOGs over a 4-year period. The median waiting time for patients from referral to SOG assessment was 0 days (IQR 0-56), and from SOG assessment to consultant review in a virtual clinic was 12 days (IQR 8-18days). After first appointment, over 60% of patients were classified as low-risk and remained within the SOG scheme. Rates of frank disagreement between SOG and consultant regarding diagnosis and proposed outcome were 5.6 and 10.4%, respectively, for tier 2 SOGs and 15.3 and 28.6%, respectively, for tier 1 SOGs.
Conclusions: The SOG scheme demonstrates acceptable levels of accuracy between SOG and glaucoma consultant. This scheme allows many stable low-risk patients to remain out of hospital eye department outpatient clinics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/02713683.2014.957326 | DOI Listing |
J Glaucoma
November 2024
Columbia University, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, 630 W. 168th Street, New York, NY 10032.
Prcis: Community-based eye health screenings that incorporated fundus photography and optometric exams in a high-risk NYC population effectively identified a higher than average number of participants that required an in-office glaucoma evaluation.
Purpose: To report glaucoma screening rates and risk factors associated with referral for in-office glaucoma evaluation in the Manhattan Vision Screening and Follow-up Study (NYC-SIGHT).
Methods: In this 5-year, cluster-randomized clinical trial, eligible individuals aged 40 and older were recruited from affordable housing developments and senior centers.
Bioengineering (Basel)
November 2024
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia.
Background/objectives: Glaucoma is the leading cause of irreversible blindness, with a significant proportion of cases remaining undiagnosed globally. The interpretation of optic disc and retinal nerve fibre layer images poses challenges for optometrists and ophthalmologists, often leading to misdiagnosis. AI has the potential to improve diagnosis.
View Article and Find Full Text PDFBMJ Case Rep
October 2024
Department of Surgery and Anaesthesia, University of Otago Wellington, Wellington, New Zealand
Myelination of the retinal nerve fibre layer (MNFL) is generally an incidental asymptomatic finding on fundus exam. While MNFL is thought to be a congenital and stationary finding, there have been cases of acquired and progressive MNFL reported. Here, we discuss a case where a girl in middle childhood presented with reading difficulties and was found to have normal vision and MNFL superior to the left optic disc.
View Article and Find Full Text PDFJ Clin Med
September 2024
II Department of Ophthalmology, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111 Szczecin, Poland.
Among the severe organ complications occurring in patients with Turner syndrome (TS), ophthalmic dysmorphia and visual impairment are usually marginalized. There are only a few studies that take into account the prevalence of ophthalmic disorders in female patients with TS. Articles in PubMed, Scholar, and Website were reviewed, considering the prevalence of various ocular disorders in patients with X chromosome deficiency.
View Article and Find Full Text PDFOphthalmol Ther
November 2024
Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!